For the latest updates on Gilead’s ongoing response to COVID-19, please click here.

LEARN ABOUT OUR RECENT APPROVAL

Our Pipeline

Pipeline icon

Leading the Way in Cell Therapy

Our pipeline of cancer therapies in the areas of cell therapy, immuno-oncology, and targeted therapies includes investigational therapies and next-generation technologies that have the power to transform the way cancer is treated. As we look to the future, we remain focused on advancing technologies that could someday address additional hematological malignancies and solid tumors.

PROGRAM

PHASE

  • PHASE 1
  • PHASE 2
  • PHASE 3
  • NDA / BLA / MAA

Axi-cel

  • PHASE 3

Trial:

ZUMA-7

 

2L DLBCL

Axi-cel

  • PHASE 2

Trial:

ZUMA-5

 

Indolent NHL

Axi-cel

  • PHASE 2

Trial:

ZUMA-14

 

3L DLBCL (+rituximab)

Axi-cel

  • PHASE 2

Trial:

ZUMA-12

 

1L HR DLBCL

Axi-cel

  • PHASE 2

Trial:

N/A

 

3L DLBCL (+mavrilimumab)

Axi-cel

  • PHASE 1

Trial:

ZUMA-11

 

DLBCL (+utomilumab)

Axi-cel

  • PHASE 1

Trial:

ZUMA-19

 

3L DLBCL (+lenzilumab)

Brexu-cel

  • PHASE 2

Trial:

ZUMA-3

 

Adult ALL

Brexu-cel

  • PHASE 2

Trial:

ZUMA-4

 

Pediatric ALL

Brexu-cel

  • PHASE 1

Trial:

ZUMA-8

 

CLL

KITE-718 (MAGE A3/A6)

  • PHASE 1

Trial:

N/A

 

Solid Tumor

KITE-439 (HPV16 E7)

  • PHASE 1

Trial:

N/A

 

Solid Tumor

Axi-cel: Axicabtagene Ciloleucel.
Brexu-cel: Brexucabtagene Autoleucel, formerly KTE-X19.
ALL: Acute lymphocytic leukemia.
CLL: Chronic lymphocytic leukemia.
DLBCL: Diffuse large B-cell lymphoma.
iNHL: Indolent non-Hodgkin lymphoma.
MCL: Mantle cell lymphoma.

The safety and efficacy of these investigational agents or investigational uses of marketed products have not been established. These uses have not been approved by the US Food and Drug Administration or other regulatory authorities. There is no guarantee that these therapies or uses will be commercialized.

Some of the content on this page is not intended for users outside the US.